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Genome-wide mutagenesis and 
multi-drug resistance in American 
trypanosomes induced by the front-
line drug benznidazole
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Arnab Pain  2, Taane G. Clark  1,3 & John M. Kelly  1
Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and affects 5–8 million people 
in Latin America. Although the nitroheterocyclic compound benznidazole has been the front-line drug 
for several decades, treatment failures are common. Benznidazole is a pro-drug and is bio-activated 
within the parasite by the mitochondrial nitroreductase TcNTR-1, leading to the generation of 
reactive metabolites that have trypanocidal activity. To better assess drug action and resistance, we 
sequenced the genomes of T. cruzi Y strain (35.5 Mb) and three benznidazole-resistant clones derived 
from a single drug-selected population. This revealed the genome-wide accumulation of mutations 
in the resistant parasites, in addition to variations in DNA copy-number. We observed mutations 
in DNA repair genes, linked with increased susceptibility to DNA alkylating and inter-strand cross-
linking agents. Stop-codon-generating mutations in TcNTR-1 were associated with cross-resistance 
to other nitroheterocyclic drugs. Unexpectedly, the clones were also highly resistant to the ergosterol 
biosynthesis inhibitor posaconazole, a drug proposed for use against T. cruzi infections, in combination 
with benznidazole. Our findings therefore identify the highly mutagenic activity of benznidazole 
metabolites in T. cruzi, demonstrate that this can result in multi-drug resistance, and indicate that 
vigilance will be required if benznidazole is used in combination therapy.
Chagas disease results from infection with the insect-transmitted protozoan parasite Trypanosoma cruzi. It is a 
life-long infection and a major cause of morbidity and mortality in many areas of Latin America1. Recently, the 
disease has also become more widespread, with large numbers of infected individuals being diagnosed within 
migrant populations, particularly in Europe and the USA2. In the initial ‘acute’ stage, which occurs 4–6 weeks 
post-infection, Chagas disease generally manifests as a transient low-level febrile condition. In children how-
ever, acute stage infections can lead to myocarditis or meningoencephalitis, and are sometimes fatal. Following 
suppression of the acute infection by a robust adaptive immune response3, the disease proceeds to a long-lasting 
asymptomatic chronic stage, which is characterised by an extremely low parasitemia. About one-third of those 
infected will eventually advance to a symptomatic stage, although this can take decades. Most of these individuals 
will develop cardiomyopathy4, or less commonly, digestive tract megasyndromes, outcomes for which there are 
few therapeutic options.
Although benznidazole has been used against chronic T. cruzi infections for almost 50 years, treatment fail-
ures are frequently reported, with non-curative outcomes varying between 6% and 50% in recent clinical tri-
als5,6. Other problematic factors include the extended treatment length (often 60–90 days) and frequent toxic 
side-effects. Furthermore, there is a demonstrated risk for cross-resistance with the other front-line drug, 
nifurtimox. This arises because both of these nitroheterocyclic agents require to be activated by the T. cruzi 
flavin-dependent mitochondrial type 1 nitroreductase, TcNTR-17,8. Our understanding of how benznidazole 
kills the parasite and why treatment is often non-curative is limited. The extent to which this is due to acquired 
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resistance or patient non-compliance remains to be determined. In addition, T. cruzi is an extremely diverse spe-
cies and there is extensive natural variation in susceptibility to benznidazole9,10, both within and between lineages. 
Despite this, there is as yet no unequivocal evidence for a link between parasite taxonomic designation and treat-
ment outcome in humans11,12, and no definitive mechanism demonstrated that accounts for natural variations in 
susceptibility. This is an area that requires further study.
Evidence suggests that trypanocidal activity could be mediated, at least in part, by DNA damage13,14 caused 
by reactive metabolites that are generated following reductive metabolism of the drug by TcNTR-115,16. Attempts 
to dissect the mechanisms underlying treatment failure have been compounded by the extremely low and focal 
nature of the parasite burden during chronic stage disease17,18 and technical difficulties in establishing parasito-
logical cure/non-cure19. To gain insight into the mechanisms of resistance, we sequenced the genomes of three 
drug-resistant clones from a single parasite population that had undergone benznidazole-selection in vitro. Here, 
we show that long-term treatment with benznidazole can give rise to genome-wide mutagenesis in T. cruzi, and 
result in phenotypic changes that include the acquisition of multi-drug resistance.
Results
Genome-wide mutagenesis in benznidazole-resistant clones. Following the isolation of three 
drug-resistant clones from a single T. cruzi population exposed to benznidazole selection, we identified a stop-co-
don-generating mutation in the TcNTR-1 gene20. However, this nonsense mutation by itself was insufficient to 
account for the high level and inter-clonal diversity of benznidazole-resistance (9–26 fold), indicating that addi-
tional mechanisms must operate. To investigate this, we sequenced the genomes of the parental T. cruzi Y strain 
and the three benznidazole-resistant clones using an Illumina HiSeq. 2500 platform (x377 coverage). Genome 
size was 35.54 Mb (48.3% GC content), distributed over 150,022 contigs. Assembly, using the SPAdes program, 
and annotation performed with the Companion Sanger Pipeline (https://companion.sanger.ac.uk) on the 3,000 
largest contigs, identified 8,289 putative protein coding genes, 5119 with predictable function. The T. cruzi CL 
Brener genome strain21 was used as reference. The parental Y strain genome sequence and those of the three 
drug-resistant clones were mapped using the BWA-mem alignment software, and single nucleotide polymor-
phisms (SNPs) were called using the SAMtools package.
We found evidence of the genome-wide accumulation of mutations in the drug-resistant clones. There was a 
total of 26,495 point mutations (Fig. 1a), with 0.42 SNPs/kb in clone 1, 0.49/kb in clone 2, and 0.45/kb in clone 3. 
32% of SNPs were in coding regions, with an equivalent number of synonymous and non-synonymous changes 
(Fig. 1b). A total of 25 nonsense/nonstop mutations were identified (Supplementary Table S1), including the 
internal stop codon within TcNTR-120. Transitions (A ↔ G or C ↔ T) were significantly more frequent than trans-
versions in clone 2, although in clones 1 and 3 the numbers were similar (Fig. 1c). 7,731 of the SNPs were present 
in all three clones and phylogenetic analysis suggested that the lineage giving rise to clones 2 and 3 diverged from 
Figure 1. Analysis of SNPs identified in T. cruzi clones selected for benznidazole-resistance. (a) Venn diagram 
illustrating the distribution of 26,495 distinct SNPs identified by genome sequencing of three drug-resistant 
clones. (b) The total number of SNPs in coding and non-coding genomic regions are shown in purple and 
yellow. The smaller circle (right) illustrates SNP distribution within coding regions: missense (green), silent 
(grey) and nonsense/nonstop (orange). (c) Classification of missense SNPs as transitions (purine ↔ purine; 
blue) or transversions (purine ↔ pyrimidine; pink). (d) Maximum-likelihood phylogenetic tree based on 
nucleotide alignment (FastTree program), showing relationship between parental and drug-resistant T. cruzi 
clones. Scale bar represents the number of substitutions per site.
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a common ancestor of clone 1 during the drug-selection process (Fig. 1d). It can be inferred therefore that SNPs 
common to clones 1 and 2, and to clones 1 and 3 (Fig. 1a), arose from point mutations acquired by the ancestral 
drug-resistant line and that subsequent differential gene conversion led to their reversion in clones 3 and 2, 
respectively.
Copy number variation (CNV) and read coverage across the data set were also assessed. Trisomy was pre-
dicted for a large region of chromosome 13 in all three drug-resistant clones, on the basis of a 1.5-fold higher 
read-coverage compared to the genome-wide average (Fig. 2b), although the fragmented nature of the reference 
genome21 prevents us from making unequivocal inferences about the entire chromosome. We also found a sim-
ilarly increased sequence coverage associated with regions (hundreds of kb) in chromosome 11 (clones 1 and 3), 
a finding supported by a control-freeC analysis. Genome plasticity has been widely observed in T. cruzi22. With 
benznidazole, where resistance can arise by a “loss-of-function” mechanism, parasites missing an entire copy of 
the chromosome containing the TcNTR-1 gene have previously been isolated7. In this present study, where we 
observed that resistance was associated with copy number increases in chromosomes 11 and 13, the most parsi-
monious explanation is that enhanced expression of one or more of the linked genes contributes to the selected 
phenotype. In clone 2, the data suggest a reversion to disomy in chromosome 11 (Fig. 2b), following divergence 
from clone 3 (Fig. 1d), although the possibility that the increased copy number was acquired independently by 
clones 1 and 3 cannot be excluded.
Deficiencies in DNA repair in drug-resistant parasites. Using gene ontology annotations, it was possi-
ble to link mutations to functional categories. The majority occurred in hypervariable regions, including the large 
and highly diverse surface antigen gene families, such as the mucins and trans-sialidases, which constitute much 
of the parasite genome23. In functional categories or metabolic pathways that have been tentatively associated 
with drug-resistance8,14,16,24–27, there were a range of SNP frequencies ranging from 0.47/kb in genes linked to 
electron transport to 0.11/kb in ABC transporter genes (Fig. 3a and b). Individually or collectively, it is implicit 
that changes to the sequence or expression of these, or other genes, have contributed to the enhanced levels 
of benznidazole-resistance. Given the extensive number of mutations in DNA repair enzymes, we investigated 
the susceptibility of the drug-resistant clones to DNA damaging agents. This revealed enhanced sensitivity to 
compounds that promote DNA alkylation (1-methyl-3-nitro-1-nitrosoguanidine) or inter-strand cross-linking 
(mechlorethamine), but not to methyl methanesulfonate, which causes double-strand breaks (Fig. 3c).
To determine if mutagenesis had compromised the infectivity of the drug-resistant clones, we inocu-
lated immunocompromised SCID mice with parasites transformed to express a red-shifted bioluminescence 
reporter17,28 (Methods). Whereas the non-resistant parental line resulted in a fulminant infection, which required 
Figure 2. Large-scale DNA copy-number variation in benznidazole-resistant clones. Histograms showing 
read-coverage for specific regions of chromosome 11 (a) and 13 (b) in parental and drug-resistant clones. 
Chromosome annotation was performed by ordering the contigs against the T. cruzi CL Brener reference 
genome21. High read peaks correspond to repetitive hypothetical protein genes, tandem repeats within 
kinesin-like genes (chromosome 11), linked histone H2A genes and short interspersed DNA sequences 
(chromosome 13). The red dotted line represents the average read-coverage across all chromosomes (single-
copy genes). Assessment by the program control-freeC is consistent with an additional copy (trisomy) of 
the regions shown in chromosome 11 [from TCRUZ.110005800 (TcCLB.509349.30) to TCRUZ.110020000 
(TcCLB.506443.80)] and chromosome 13 [from TCRUZ_130005000 (TcCLB.510165.60) to TCRUZ_130019000 
(TcCLB.508325.90)]. Chromosome 11 in clone 2 did not display an increased read-coverage compared to the 
genome-wide average.
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the mice to be euthanised after 28 days, infections with drug-resistant clones were asymptomatic, and there was 
an extremely low parasite burden (Fig. 3d). This loss of fitness may reflect that infectivity was not a trait under 
selection during the continuous in vitro culturing used to generate benznidazole-resistant parasites (Methods). 
Studies had previously shown that there were no significant differences in the rate of intracellular amastigote 
replication or infectivity of cultured mammalian cells20.
Multi-drug resistance following benznidazole selection. As predicted for parasites with a dis-
rupted TcNTR-1 gene, the three clones displayed cross-resistance to other nitroheterocyclic agents (Fig. 4a–d; 
Supplementary Table S2), including nifurtimox, a drug which is also used to treat T. cruzi infections, and fex-
inidazole, a drug which has undergone clinical trials against Chagas disease. The level of resistance (2–5 fold) 
was consistent with that previously observed for nitroheterocyclic compounds following disruption of one 
copy of TcNTR-17,29. It can therefore be inferred that the other, as yet unknown mechanisms that lead to the 
enhanced benznidazole-resistance, do not contribute significantly to additional levels of cross-resistance against 
other nitroheterocyclic drugs. Unexpectedly, we found that each of the clones were also highly resistant to the 
anti-fungal agent posaconazole (6–22 fold, Fig. 4e). Although posaconazole monotherapy recently failed in 
clinical trial against Chagas disease5,30, its use in combination with benznidazole has been discussed31–33 and 
subjected to preliminary trial in humans30. Posaconazole is an ergosterol biosynthesis inhibitor that targets lanos-
terol 14α-demethylase (CYP51)34,35, a mechanism of action that shares no known biochemical overlap with that 
of benznidazole. In the drug-resistant clones, there were no mutations detected in CYP51, and the gene is not 
located on either of the chromosomes (11 and 13) which displayed increased copy number. Mutations were 
noted in the 5’-upstream region of CYP51, and in the coding regions of other genes linked with ergosterol bio-
synthesis (Supplementary Figure S1). However, these did not affect the intracellular level of CYP51, as judged 
by binding between the enzyme and posaconazole conjugated with the fluorophore boron-dipyrromethene36,37 
(Supplementary Figure 2). To exclude the possibility that TcNTR-1 depletion might perturb susceptibility to 
posaconazole, we tested its activity against two cloned T. cruzi cell lines (Methods) in which we had deleted one 
copy of the gene (Fig. 4f). There was no significant difference compared to the parental parasites.
Figure 3. Genetic and phenotypic changes in benznidazole-resistant clones. (a) Total point mutations in 
genes linked to DNA repair, redox metabolism, electron transport, cell growth and proliferation, and ABC 
transporter activity, in each of the three clones. The colour scale indicates the number of mutations per gene: 
1 (+), 2 (++), or 3 or more (+++). (b) Average SNPs/kb in genes from different functional categories in the 
3 clones. Synonymous and non-synonymous SNPs are shown. (c) Sensitivity of parental and drug-resistant 
parasites to the DNA damaging agents methyl-3-nitro-1-nitrosoguanidine (MNNG), mechlorethamine (ME) 
and methyl methanesulfonate (MMS) (Methods). Statistical analysis was performed using one-way analysis of 
variance; p values, respectively: 0.02, 0.01, 0.02 (MNNG); 0.002, 0.003, 0.02 (ME). (d) Bioluminescence imaging 
of SCID mice infected i.p. with parental and drug-resistant clones (104 tissue culture trypomastigotes). Parasites 
were genetically transformed to express the luciferase reporter gene PpyRe9h17,28 (Methods). Ventral images of 
representative mice (n = 3) are shown, with the number of days post-infection given above. Heat maps indicate 
the intensity of bioluminescence from low (blue) to high (red) (log10 scale); the minimum and maximum 
radiances for the pseudocolour scale are shown. The mice infected with the parental Y strain required 
euthanization on day 28, in accordance with animal welfare requirements (Methods).
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Discussion
Investigating the underlying causes of treatment failure in humans has been challenging in the case of T. cruzi 
infections5,6. Reasons include the possible influences of host and parasite genetics, the effects of toxicity on com-
pliance, difficulties in demonstrating parasitological cure, the unresolved contribution of drug-resistance and 
the possibility of re-infection/co-infection. With benznidazole, there are no data available from clinical trials 
that provide insight into the mechanisms of resistance or the precise mode of drug action in infected individ-
uals. Evidence from in vitro studies suggest that the pivotal step in both drug activity and resistance involves 
bio-activation of the drug by the nitroreductase TcNTR-17–9,15,16. This gives rise to toxic metabolites that react 
with a range of biological molecules (for review, see ref.8,29). However, given the high level of resistance that is 
achievable in vitro (Fig. 4, as example), and the wide range of natural susceptibility to benznidazole9,10, it is clear 
that other mechanisms can also contribute. For example, several other parasite genes have been identified that 
could act through alternative bioactivation38, alleviation of oxidative stress39, or increased efflux26. In the context 
of DNA, electrophilic drug metabolites, increased oxidative stress resulting from drug adduct-thiol conjugation, 
and the generation of oxidised nucleotides such as 8-oxo-guanine, have been implicated as potential mediators of 
mutagenesis in benznidazole-treated T. cruzi14–16,40,41.
Here, we show that benznidazole-induced mutagenic effects can be extensive and genome-wide in T. cruzi, 
with a range of phenotypic consequences, including reduced DNA repair capacity and multi-drug resistance. 
These types of outcome have many parallels with the situation in drug-resistant cancer, where selective pressure, 
coupled with the early acquisition of defects in the DNA damage repair machinery, can drive the development 
of multi-drug resistance through mechanisms linked with chromosome instability and an increased propensity 
to acquire mutations42,43. In a similar way, our results suggest that in T. cruzi under benznidazole-selection, the 
combined effects of electrophilic drug metabolites and deficiencies in DNA repair, which could arise early in the 
process, might also act in concert to create a hypermutagenic environment that can drive the development of 
enhanced resistance and other phenotypic changes (Fig. 3d). Reduced infectivity was one was one of the acquired 
traits common to the drug-resistant clones. This phenotype could have arisen as a result of sequence changes at 
a single locus, or could represent the collective effect of multiple mutations. It will be important to determine 
whether this loss of fitness is a frequent or inevitable consequence of benznidazole-resistance, or whether selec-
tive pressures encountered in an in vivo context would be sufficient to exclude this particular outcome.
The current benznidazole dosing regimen involves daily administration for periods of 60 days or more, with 
many patients failing to complete treatment because of toxic side-effects5,6,30. Partly to avoid this, combination 
therapy with posaconazole has been suggested as a treatment option that might allow a reduction in patient expo-
sure to benznidazole30. On the basis that benznidazole and posaconazole activities are not thought to overlap, it 
Figure 4. Multi-drug resistance following benznidazole-selection. (a–e) EC50 values were obtained (Methods) 
for the parental Y strain (P) and drug-resistant clones 1–3 (epimastigotes) against benznidazole, nifurtimox, 
fexinidazole, fexinidazole sulfone and posaconazole. The fold-resistance is indicated above each bar. (f) 
Benznidazole and posaconazole susceptibility of parental parasites and two genetically modified clones in which 
one copy of the TcNTR-1 gene had been deleted. Each experiment was performed 3 times in triplicate.
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has also been assumed that the generation of cross-resistance using this regimen would be unlikely. However, our 
results show that this need not be the case. Parasites selected on benznidazole alone were found to have developed 
high-level resistance to posaconazole (Fig. 4e). This outcome could not be attributed to changes in the CYP51 
gene, and presumably results from the effects of other mutation(s), either individually or collectively. Whatever 
the precise mechanism, these findings have implications for future Chagas disease strategies, suggesting that com-
bination therapy involving benznidazole will require careful monitoring, irrespective of the secondary drug used. 
Although caution must be displayed in extrapolating findings made in vitro, our data further highlight an urgent 
need for studies aimed at isolating parasites from patients following non-curative benznidazole therapy, to deter-
mine if induced mutagenesis and acquired drug-resistance have contributed to treatment failure. However, there 
will be significant technical and analytical issues associated with this. As mentioned previously44, these include 
complexity resulting from multi-clonal infections, possible stage-specific differences in parasite susceptibility, the 
tissue origin of recrudescence, interplay with the immune system, and finally, difficulties in isolating parasites 
from chronic chagasic patients, both before and after treatment.
Methods
Isolation of benznidazole-resistant clones. T. cruzi (Y strain) was cultured as epimastigotes in sup-
plemented RPMI-1640 medium at 28 °C45. Parasites were selected for benznidazole-resistance by culturing in 
the continuous presence of 182 μM benznidazole for 10 passages. From the 11th until the 15th passage, the drug 
concentration was increased in 10 μM steps46. The total selection period was 4 months. Parasites were then cloned 
by limiting dilution20 and the extent of benznidazole-resistance assessed. The resistance phenotype was found to 
be unchanged after 6 months continuous culturing in the absence of benznidazole46.
Genome sequencing. Genomic DNA was prepared from three drug-resistant clones and the parental strain, 
and then submitted to paired-end sequencing (100 bp) using an Illumina HiSeq. 2500 platform. Assembly of 
high-quality reads was conducted using SPAdes assembly program, with genome annotation on the 3,000 larg-
est contigs performed by the Companion Sanger Pipeline (https://companion.sanger.ac.uk), using the T. cruzi 
CL Brener strain21 as reference. Mapping of the parental population to the three drug-resistant clones and SNP 
analysis were performed using the BWA-mem alignment software and SAMtools package, respectively. Gene 
functional categories were classified based on GO annotations. Copy number variation was assessed using the 
program control-freeC (http://bioinfo-out.curie.fr/projects/freec/tutorial.html). Sequence data from this paper 
are available on the website PathogenSeq LSHTM (http://pathogenseq.lshtm.ac.uk/t_cruzi/) and at the European 
Nucleotide Archive (http://www.ebi.ac.uk/ena/) under the accession no. PRJEB14637; clone 1 (ERS1913021), 
clone 2 (ERS1913022), clone 3 (ERS1913023), parental Y strain (ERS1913024).
Genetic modification of T. cruzi and assessment of infectivity by in vivo imaging. The red-shifted 
luciferase gene PpyRE9h was integrated into rRNA loci in three drug-resistant clones and the parental Y strain 
using the construct pTRIX2-RE9h17 (Fig. 3d). Clones expressing comparable levels of bioluminescence were cul-
tured under conditions that promote differentiation into metacyclic trypomastigotes17. The resulting parasites 
were used to infect rat myoblast L6 monolayers at a ratio of 10 metacyclics per host cell. Following incubation at 
37 °C under 5% CO2 for 7 days, tissue culture trypomastigotes were collected from the supernatant and female 
CB17 SCID mice (aged 8–12 weeks and bred in-house) were infected i.p. with 104 trypomastigotes. Animals 
were maintained under specific pathogen-free conditions in individually ventilated cages, and experienced a 
12 hour light/dark cycle, with access to food and water ad libitum. To monitor infections, mice were injected 
with 150 mg kg−1 d-luciferin every 7 days and imaged using an IVIS Lumina II system (Caliper Life Science), as 
described previously17. Mice injected with the parental line developed fulminant infections and were euthanized 
at or before humane end-points by exsanguination under terminal anaesthesia. All animal work was performed 
under UK Home Office licence 70/8207 and approved by the London School of Hygiene and Tropical Medicine 
Animal Welfare and Ethical Review Board.
To generate parasites in which one copy of the Tc-NTR-1 gene had been disrupted, bioluminescent T. cruzi 
CL Brener epimastigotes17,47 were transfected as described previously7. Briefly, parasites were electroporated with 
plasmid pKO-NTR-BLA which had been linearised by Kpn I/Sac II digestion, and blasticidin-resistant parasites 
were isolated, cloned and checked by PCR to confirm integration and disruption.
Parasite susceptibility to drugs or DNA damaging agents. Epimastigotes were seeded at 
2.5 × 105 ml−1 in 96-well plates in the presence of a range of concentrations of nitroheterocyclic compounds (ben-
znidazole, nifurtimox, fexinidazole, or fexinidazole sulfone), posaconazole, or DNA damaging agents (MNNG, 
ME and MMS). Plates were incubated for 4 days at 28 °C, with resazurin added for the final 48 hours. The plates 
were then read in a Spectramax plate reader and the EC50 values determined using GraphPad Prism. Statistical 
analysis was performed using one-way analysis of variance, with significance for p values < 0.05 (*).
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